Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claims on malignancy risk and teratogenicity/fetal harm with pregnancy prevention/effective contraception timing are directly supported by the provided FDA label sections (5.1, 4, 5.2, 8.1, 8.3, and 17). No contradictions or label-conflicting statements were identified.
Category Scores
Accurate Statements
MAVENCLAD has an increased malignancy risk.
Supported by Warnings and Precautions (5.1): “Treatment with MAVENCLAD may increase the risk of malignancy…” with comparative incidence vs placebo; reinforced by patient counseling (17) and contraindication in current malignancy (4).
MAVENCLAD is contraindicated in patients with current malignancy.
Contraindications (4): “MAVENCLAD is contraindicated… in patients with current malignancy [see Warnings and Precautions (5.1)].”
MAVENCLAD may cause fetal harm/teratogenicity and requires pregnancy prevention/effective contraception for defined periods.
Risk of Teratogenicity (5.2): “MAVENCLAD may cause fetal harm…” plus contraception/pregnancy prevention “for 6 months after the last dose… and for 14 weeks for males”; also reflected in Contraindications (4), Pregnancy (8.1), and Reproductive Potential (8.3).
Pregnancy should be excluded before initiation of each treatment course.
Reproductive potential (8.3): “Pregnancy should be excluded before the initiation of each treatment course of MAVENCLAD.”
Unsupported Statements
Contradictions
Important Omissions
Whether a boxed warning is present for MAVENCLAD (the evaluation states no boxed warning identified in the provided content).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated are consistent with the provided label warnings/contraindications regarding malignancy risk and fetal harm with contraception timing requirements, which are safety-relevant.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The statement about boxed warning presence is not determinable from the provided label excerpts.
Suggested Improvement
Limit statements about boxed warnings to what is explicitly shown in the provided label text (or avoid that assertion entirely) while keeping the malignancy and reproductive-risk claims tied to specific labeled sections.